Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: Analysis in primary cell cultures of human prostate carcinoma

Journal of Inflammation (United Kingdom)

Volumn 10, Issue 1, 2013, Pages

  Silvestri, Ida ^a   Cattarino, Susanna ^b   Aglianò, Annamaria ^a   Nicolazzo, Chiara ^a   Scarpa, Susanna ^b   Salciccia, Stefano ^b   Frati, Luigi ^b   Gentile, Vincenzo ^b   Sciarra, Alessandro ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Caspase detection; Cell cultures; Inflammation; Proliferation; Prostate neoplasm

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SABAL EXTRACT; TRANSCRIPTION FACTOR RELA;

AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CCL 2 GENE; CCL 5 GENE; CELL COUNT; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COX 1 GENE; COX 2 GENE; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 6 GENE; IMMUNOFLUORESCENCE; IN VITRO STUDY; INOS GENE; MALE; PRIMARY CELL CULTURE; PROSTATE CARCINOMA; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

SERENOA REPENS;

EID: 84874936396     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-10-11     Document Type: Article

References (33)

1. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R, Eur Urol 2009 55 864 875 10.1016/j.eururo.2008. 11.011 19027219
2. Inflammation and chronic prostatic diseases: evidence for a link? Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V, Eur Urol 2007 52 964 972 10.1016/j.eururo.2007.06.038 17618043 (Pubitemid 47332058)
3. Prostate cancer as a model for tumour immunotherapy. Drake CG, Nat Rev Immunol 2010 10 580 593 10.1038/nri2817 20651745
4. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. De Nunzio C, Kramer G, Marberger M, Eur Urol 2011 60 1 106 117 10.1016/j.eururo.2011.03.055 21497433
5. Polymorphisms of pro- inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Caruso C, Balistreri CR, Candore G, Cancer Immunol Immunother 2009 58 1919 1933 10.1007/s00262-009-0658-y 19221747
6. Inflammation, infection, and prostate cancer. Klein EA, Silverman R, Curr Opin Urol 2008 18 315 319 10.1097/MOU.0b013e3282f9b3b7 18382242 (Pubitemid 351489383)
7. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. Chung LW, Baseman A, Assikis V, Zhau HE, J Urol 2005 173 1 10 20 10.1097/01.ju.0000141582.15218.10 15592017 (Pubitemid 39627663)
8. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C, J Steroid Biochem 1984 20 1 521 523 10.1016/0022-4731(84)90265-6 6200701 (Pubitemid 14125121)
9. Effects of Permixon (Sereprostat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. International workshop in Urology. Ragab A, Ragab-Thomas JMF, Delhan A, New trends in bladder cancer chemotherapy-new trends in BPH etiopathogenesis Acta Medica, Di Silverio F, Steg A, 1998 293 296 23040257
10. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López FA, Eur Urol 2003 44 5 549 555 10.1016/S0302-2838(03)00368-3 14572753 (Pubitemid 37328630)
11. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign 2003 prostatic hypertrophy patients. Di Silverio F, D'Eramo G, Lubrano C, Eur Urol 1992 21 4 309 314 1281103
12. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P, Prostaglandins Leukot Essent Fatty Acids 1997 57 3 299 304 10.1016/S0952-3278(97)90548-2 9384520 (Pubitemid 27454265)
13. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, Prostate 2000 45 3 259 266 10.1002/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G 11074529
14. Primary cell cultures as models of prostate cancer development. Peehl DM, Endocr Relat Cancer 2005 12 1 19 47 10.1677/erc.1.00795 15788637 (Pubitemid 40477086)
15. Are primary cultures realistic models of prostate cancer? Peehl DM, J Cell Biochem 2004 91 1 185 195 10.1002/jcb.10691 14689590
16. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P, Eur Urol 1998 33 3 340 347 10.1159/000019570 9555564 (Pubitemid 28140436)
17. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization. Petrangeli E, Lenti L, Buchetti B, J Cell Physiol 2009 219 1 69 76 10.1002/jcp.21648 19067321
18. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. Bayne CW, Ross M, Donnelly F, Habib FK, J Urol 2000 164 876 881 10.1016/S0022-5347(05)67330-2 10953171 (Pubitemid 30637649)
19. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Ravenna L, Di Silverio F, Russo MA, Prostate 1996 29 4 219 230 10.1002/(SICI)1097-0045(199610)29:4<219::AID-PROS3>3.0.CO;2-6 8876705 (Pubitemid 26365287)
20. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Bayne CW, Donnelly F, Ross M, Habib FK, Prostate 1999 40 4 232 241 10.1002/(SICI)1097-0045(19990901)40: 4<232::AID-PROS4>3.0.CO;2-0 10420151 (Pubitemid 29398049)
21. Caspases: enemies within. Thornberry NA, Lazebnik Y, Science 1998 281 1312 1316 9721091 (Pubitemid 28406817)
22. Apoptotic pathways: paper wraps stone blunts scissors. Green DR, Cell 2000 102 1 1 4 10.1016/S0092-8674(00)00003-9 10929706
23. Saw Palmetto induced growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Yang Y, Ikezoe T, Zheng Z, Hirokuni T, Koeffler HP, Zhu WG, Int J Oncol 2007 31 593 600 17671686
24. Effect of Permixon on human prostate cell growth: lack of apoptotic action. Hill B, Kyprianou N, Prostate 2004 61 73 80 10.1002/pros.20088 15287095 (Pubitemid 39095696)
25. On chromosomal instability: what is the karyotype of your 32D CI3 cell line. Aglianò AM, Santangelo C, Silvestri I, Gazzaniga P, Giuliani L, Naso G, Frati L, Castiglia R, Blood 2000 95 11 3636 3637 10877550 (Pubitemid 30428506)
26. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC, Clin Cancer Res 2003 9 1 370 376 12538490 (Pubitemid 36109754)
27. Nuclear factor-kappaB in cancer development and progression. Karin M, Nature 2006 441 7092 431 436 10.1038/nature04870 16724054 (Pubitemid 44050137)
28. Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-κB and crosstalk between the extrinsic and intrinsic apoptoticpathways. Huang CH, Guh JH, Chen GS, Lu PH, Chern JW, Naunyn-Schmied-Arch Pharmacol 2010 382 159 169 10.1007/s00210-010- 0528-3
29. Temporal pattern of NFkappaB activation influences apoptotic cell fate in a stimuli-dependent fashion. Fan C, Yang J, Engelhardt JF, J Cell Sci 2002 115 4843 4853 10.1242/jcs.00151 12432072 (Pubitemid 36054637)
30. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kB. Loveridge CJ, MacDonald ADH, Thoms HC, Dunlop MG, Stark LA, Oncogene 2008 27 2648 2655 10.1038/sj.onc.1210891 18059344 (Pubitemid 351550873)
31. c-Src dependency of NSAID-induced effects on NF{kappa}B-mediated apoptosis in colorectal cancer cells. Brady RR, Loveridge C, Dunlop MG, Stark LA, Carcinogenesis 2011 32 7 1069 1077 10.1093/carcin/bgr077 21551129
32. Failure of apoptosis and activation on NFkappaB by colecoxib and aspirin in lung cancer cell lines. Gradilone A, Silvestri I, Scarpa S, Morrone S, Ganidni O, Pulcinelli FM, Gianni W, Frati L, Aglianò AM, Gazzanica P, Oncol Rep 2007 17 4 823 828 17342322
33. Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Gazzaniga P, Silvestri I, Gradiolne A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L, Aglianò AM, Anticancer Drugs 2007 18 2 179 185 10.1097/CAD.0b013e328010ef47 17159604 (Pubitemid 44967428)